Our Mission
To empower end stage cancer patients with hope and awareness, as well as provide a revolutionary treatment approach that utilizes the body’s natural defense mechanisms against tumor life support systems.
About Res Nova Bio
Targeting Tumor Life Support Systems
Res Nova Biologics uses immunotherapy and the similarities between pregnancy and cancer to treat advanced breast cancer. While on opposite ends of the spectrum, both cancer and pregnancy share common characteristics such as the way they grow, the way they invade the body and the way they manipulate the immune system to survive.
Our approach takes advantage of these factors and attacks the lifeline of cancer, its blood vessels. Cancer grows and spreads through a process called angiogenesis or blood vessel formation. Targeting the structures that feed the tumor, make them vulnerable to the body’s immune system, and make therapies such as chemo, radiation or other treatments more effective.
The technologies we’ve developed are safe and non-toxic, specific to cancer associated blood vessels, make them more visible to the immune system, target multiple cancer causing antigens in the tumor microenvironment and teaches the body to remember and destroy these threats. Moreover, our immunotherapies can overcome the problems associated with traditional treatment modalities, such as drug resistance and autoimmunity.
Our company values excellence, integrity and advocacy. It is a place where problems get solved and lives are transformed.
The Science
Cancer associated blood vessels are the life line of a tumor and supplies it with the nutrition it needs to continue growing.
Without a constant blood supply, cancerous cells do not have the capability to grow more than 1-2 millimeters.
Treatment approaches targeting tumor blood vessel growth began in the 1990s with the rationale that: a) the cells producing blood vessels, called “endothelial cells” originate from noncancerous tissue and do not mutate; b) delivering drugs to blood vessels is more effective than delivering drugs to the tumor for specific reasons. Studies have shown that tumors contain multiple cell types and therapies cannot penetrate past the necrotic tissue of abnormal cells. However, blood vessels are directly exposed to circulation, eliminating the need to target tumors from within; and c) due to the biology of interaction between new blood vessels and tumors, killing one blood vessel cell results in the death of 200-300 cancer cells.
Based on the above rationale the FDA has approved several drugs which treat cancer through blocking the ability of these tumors to create new circulation to feed itself. Unfortunately, these approaches have not been effective in breast cancer. Res Nova seeks to overcome this through using immunotherapy against cancer specific blood vessels.
